We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+22.9%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.54B
AUM Growth
+$381M
Cap. Flow
+$151M
Cap. Flow %
9.83%
Top 10 Hldgs %
42.85%
Holding
66
New
16
Increased
21
Reduced
18
Closed
6

Top Buys

Rank Stock Value
1
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$31.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.7M
3
RGNX icon
Regenxbio
RGNX
+$24.5M
4
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$23.6M
5
ICUI icon
ICU Medical
ICUI
+$23.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$51.5M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$47.7M
3
ARRY
Array Biopharma Inc
ARRY
+$41M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$39.4M
5
CNC icon
Centene
CNC
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.68%
2 Financials 0.93%
3 Miscellaneous 0.83%
4 Communication Services 0.56%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNCE
26
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$22.5M 1.46%
+1,114,160
New +$23.6M
IMMU
27
DELISTED
Immunomedics Inc
IMMU
$21.9M 1.42%
+3,380,846
New +$17.1M
PTHN
28
DELISTED
Patheon N.V.
PTHN
$21.8M 1.41%
826,843
+386,123
+88% +$11.3M
DPLO
29
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$20M 1.3%
1,254,342
+1,101,025
+718% +$15.9M
ELGX
30
DELISTED
Endologix Inc
ELGX
$19.7M 1.28%
271,739
+151,050
+125% +$9.99M
ESRX
31
DELISTED
Express Scripts Holding Company
ESRX
$19.4M 1.26%
293,807
-44,993
-13% -$3.1M
NSTG
32
DELISTED
NanoString Technologies, Inc.
NSTG
$18.6M 1.21%
934,424
-3,533
-0.4% -$67.2K
LJPC
33
DELISTED
La Jolla Pharmaceutical Company
LJPC
$18M 1.17%
+604,470
New +$15.4M
CTLT
34
DELISTED
CATALENT, INC.
CTLT
$17.7M 1.15%
+624,000
New +$17.5M
CASC
35
DELISTED
Cascadian Therapeutics, Inc.
CASC
$16.9M 1.09%
+4,072,424
New +$17.1M
PRXL
36
DELISTED
Parexel International Corp
PRXL
$16.4M 1.07%
+260,231
New +$17.2M
SPNC
37
DELISTED
Spectranetics Corp
SPNC
$16.2M 1.05%
557,189
+369,562
+197% +$9.85M
BPMC
38
DELISTED
Blueprint Medicines
BPMC
$16M 1.04%
+400,000
New +$14.3M
IMGN
39
DELISTED
Immunogen Inc
IMGN
$15.4M 1%
+3,984,734
New +$11.6M
SYRS
40
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$15.2M 0.99%
95,274
+430
+0.5% +$52.5K
EHTH icon
41
eHealth
EHTH
$38.4M
$14.3M 0.93%
1,191,334
+193,713
+19% +$2.24M
BOLD
42
DELISTED
Audentes Therapeutics, Inc
BOLD
$14M 0.91%
820,836
-11,900
-1% -$192K
CTMX icon
43
CytomX Therapeutics
CTMX
$699M
$11.8M 0.76%
681,892
-15,100
-2% -$199K
MCK icon
44
McKesson
MCK
$104B
$11.6M 0.75%
+78,300
New +$11.5M
CRL icon
45
Charles River Laboratories
CRL
$13.9B
$10.9M 0.71%
121,307
-125,800
-51% -$10.7M
NVTA
46
DELISTED
Invitae Corporation
NVTA
$8.98M 0.58%
812,240
-252,762
-24% -$2.42M
MODN
47
DELISTED
MODEL N, INC.
MODN
$8.59M 0.56%
822,314
+12,400
+2% +$121K
PRQR icon
48
ProQR Therapeutics
PRQR
$323M
$7.77M 0.5%
1,553,225
-24,949
-2% -$110K
FATE icon
49
Fate Therapeutics
FATE
$291M
$6.46M 0.42%
1,419,058
– –
DVAX
50
DELISTED
Dynavax Technologies
DVAX
$6.07M 0.39%
1,019,491
-30,300
-3% -$146K
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2017 Portfolio in Review

As of Q1 2017, Redmile Group held 66 positions worth $1.54B, up 33% from $1.16B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Redmile Group deployed $151M of net new capital in Q1 2017, opening 16 new positions and adding to 21 existing holdings. Its largest new stake was Syneos Health, Inc. Class A Common Stock: 633,779 shares worth $29.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $51.5M trimmed.

  • Redmile Group's largest Q1 2017 buy was Syneos Health, Inc. Class A Common Stock: 633,779 shares worth $29.1M.
  • Redmile Group added most to Alder Biopharmaceuticals in Q1 2017, an estimated $21.9M increase.
  • Redmile Group's biggest Q1 2017 reduction was Seagen Inc. Common Stock, cutting an estimated $51.5M.
  • Redmile Group fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $47.7M.
  • Redmile Group's ten largest holdings make up 43% of its $1.54B portfolio in Q1 2017.
  • Redmile Group opened 16 new positions and closed 6 in Q1 2017.
  • Redmile Group's portfolio value rose 33% quarter-over-quarter to $1.54B.

Based on Redmile Group's 13F filing for Q1 2017, filed 15 May 2017.